Objective: This meta-analysis was performed to assess whether arginine supplementation could reduce preeclampsia or eclampsia incidence and improve the outcomes of hypertensive disorders in pregnancy, and to evaluate the safety of L-arginine supplementation. Methods: The Cochrane Central Register of Controlled Trials (2011), MEDLINE (1980 -2011 ) and Embase (1980 -2011 were searched through July 2012, and randomized controlled trials (RCTs) comparing intravenous and/or oral L-arginine supplementation with placebo, or RCTs comparing any treatment with arginine were included. Qualities of RCTs were assessed with the Jadad method. Meta-analyses were performed with fixed-or random-effects models according to heterogeneity of studies. Results: Data from seven RCTs involving 916 patients were enrolled. The meta-analysis showed L-arginine was more effective in reducing preeclampsia or eclampsia incidence (odds ratio 0.384; 95% confidence limits 0.25, 0.58) than the placebo; meanwhile, L-arginine could prolong pregnancy weeks (MD 11.54; 95% CL 5.23, 17 .85) than placebo; and its effect on blood pressure was unbalanced (diastolic pressure (MD 4.86; 95% CL 4.19, 5.52) and systolic pressure (MD 3.20; 95% CL −1.54, 7.94)) while the difference in increased neonatal weight (MD 256.24; 95% CL −28.66, 541.13) was not clear. Three of these studies reported some adverse effects, and no teratogenic or lethal effects were noted. Conclusion: This study demonstrates L-arginine supplementation is superior to placebo in lowering diastolic pressure and prolonging pregnancy in patients with gestational hypertension with or without proteinuria, but the effect on lowering systolic pressure and increasing neonatal weight was not statistically significant.
Introduction
Hypertensive disorder of pregnancy is one of the most common perinatal diseases, 1 accounting for about 10%−15% of pregnancies. 2, 3 It can be defined as the onset of hypertension after the 20th week of pregnancy, with systolic and diastolic pressure higher than 140 and 90 mm Hg on at least two different occasions. 4 However, the pathogenesis of preeclampsia remains elusive, and prevention through routine supplementations with calcium, magnesium, omega-3 fatty acids, or antioxidant vitamins are ineffective. [5] [6] [7] [8] To date, it is certain that pregnancy has been reported to be a state of relative arginine deficiency. 9 Arginine is one kind of essential amino acid, physiologically active in L-form, which is synthesized by endothelial cells and excreted with urine in vivo. 10 Arginine has been well recognized as a drug to treat variable diseases and symptoms, as well as a dietary tonic. L-arginine is the substrate of nitric oxide (NO), a potent vasodilator, which may play a major role in regulating blood pressure. 11 Studies in animal models show that the L-arginine-NO system is upregulated during pregnancy, [12] [13] [14] and hypertension, proteinuria, fetal growth retardation, and glomerular damage could be induced by blockade of NO synthesis, while hypertension induced by NO synthesis inhibition could be reversed by L-arginine supplementation. In humans, administration of L-arginine seems to improve uterine-placental circulation and decrease maternal blood pressure, [15] [16] [17] and oxidative stress was demonstrated as a key factor involved in the development of endothelial dysfunction and preeclampsia. [18] [19] [20] Therefore, L-arginine might be a new therapeutic option in hypertensive disorder of pregnancy.
Treatment with L-arginine seems to be promising for reducing blood pressure and prolonging pregnancy. Some studies have published positive results on the antihypertensive effect of L-arginine. L-arginine was also reported to have therapeutic effects on other pregnancy complications. However, some other trials reported insignificant therapeutic effects of arginine. Our review aimed to assess whether arginine supplementation can reduce the incidence of preeclampsia or eclampsia, decrease maternal blood pressure, and prolong pregnancy in hypertensive disorders of pregnancy, and to evaluate the safety of L-arginine supplementation.
Materials and methods

Selection of published studies
We developed a search strategy to use MeSH terms and free keyword terms of "hypertensive disorder of pregnancy," "preeclampsia," "eclampsia," "HELLP-syndrome," "maternal hypertension," "pregnancy-induced hypertension," and "arginine." We searched these terms from the following databases: the Cochrane Central Register of Controlled Trials (2011), MEDLINE (1980 MEDLINE ( -2011 , and Embase , combined search terms with Boolean operators, and identified randomized controlled trials (RCTs) without language restrictions. We also searched relevant studies manually in the latest journals.
The inclusion criteria were RCTs comparing intravenous and/or oral L-arginine supplementation with placebo, or RCTs comparing any treatment with arginine, while publications in abstract form alone were excluded.
Pregnant women with hypertensive disorder of pregnancy consisting of gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome were included. The definition of hypertensive disorder in pregnancy was described as the following criteria according to the report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. 4 A flow diagram of the study selection process is summarized in Figure 1 .
Data extraction
We independently extracted data from identified studies into a standard electronic data extraction form. This was performed by two authors (Gui and Jia). Discrepancies were discussed between the reviewers and resolved by consensus. Corresponding authors were contacted for additional information.
Statistical analysis
For studies with more than one control group, we analyzed the data for the placebo control group only where the study balance was controlled. Meta-analyses were performed with fixed-or random-effects models according to the heterogeneity of studies. Heterogeneity between results, interpreted as the proportion of the total variation in estimated risk ratios that is due to between-study heterogeneity instead of chance, was assessed with I 2 , and I 2 values of 25%, 50%, and 75% corresponding to low, moderate, and high levels of heterogeneity, respectively. 21, 22 Subgroup analysis would, if appropriate, be performed for the following items: therapeutic versus prophylactic doses of L-arginine, arginine versus placebo, and arginine compared with no treatment, because the route and dosage of L-arginine of these trials was complex ( Table 1 ). If subgroup analysis could not remove the heterogeneity, the random-effects model would be chosen. During the analysis of the antihypertensive effect of L-arginine, we excluded one study by Neri et al., 23 for the unextractable data. Studies meeting the inclusion criteria would be assessed for methodological quality by the Jadad method.
Results
Characteristics of studies
We searched the electronic databases mentioned above, and the primary searching outcomes of RCTs of arginine supplementation for hypertensive disorder of pregnancy included 393 papers. After removing duplicates and papers that were less related according to the abstracts, there were 14 papers left. Two performers first read the full text of these 14 papers, and excluded the papers that have only abstracts or were less related. We selected eight RCTs about arginine supplementation for patients with hypertensive disorder of pregnancy. One pair of research articles were from the same research project, 24, 25 and we ultimately got seven RCTs from 2004 to 2011. 34 29. Among the 916 patients enrolled in these trials, 65 patients were lost to follow-up because of refusal, instability of maternal or fetal conditions, or necessity of termination of pregnancy. A total of 431 patients received L-arginine orally or intravenously, while 420 patients received placebo or regular treatment (Table 1) . Table 2 describes the quality of the enrolled RCTs. Four papers described their methods of randomization, all of which used a computer-generated random list, and allocation concealment was described. For the remaining papers, the authors did not state the randomization and blinding methods explicitly. All the papers were assessed with the Jadad method, 26 according to which a Jadad score between 1 and 3 referred to a low-quality study. One paper from meta-analysis was excluded for a Jadad score lower than 4 to eliminate uncertain risk of bias, 27 and the others were accepted ( Table 2) . Tables 3 and 4 describe the characteristics and baseline of enrolled trials. Staff et al. 34 
Preeclampsia incidence
Only two studies, 524 subjects included, analyzed the relationship between supplement of L-arginine and preeclampsia incidence, and the analysis suggested that L-arginine is more effective in reducing preeclampsia or eclampsia incidence than placebo (odds ratio 0.384; 95% confidence limits (CL) 0.25, 0.58). The heterogeneity of diastolic pressure changes ( I ² = 9%, p = 0.29, Chi² = 1.10) was acceptable, therefore, we used the fixed-effects model to analyze the data, in which the reduced incidence of preeclampsia in the L-arginine group as compared with placebo group was significant ( Figure 2 ).
Latency
In the analysis for latency, which means the time from randomization to delivery, 135 patients in two studies were extracted, and we demonstrated that L-arginine is more effective in prolonging latency than placebo (mean difference (MD) 11.54; 95% CL 5.23, 17.85). The fixed-effects model was used because of acceptable heterogeneity ( I ² = 0%, p = 0.88, Chi² = 0.02) ( Figure 3 ).
Systolic pressure
There are four studies with 204 subjects that referred to the antihypertensive effect of arginine, but the heterogeneity among them was significant ( I ² = 61%, p = 0.05, Chi² = 7.67) on systolic pressure changes. Consequently, we performed a subgroup analysis, I ² between subgroups was 0%, but the total I ² was still 61%. The heterogeneity was still large; for this reason we used a random-effects model to analyze the data. There was no statistically significant difference between the L-arginine and placebo group (MD 3.20; 95% CL − 1.54, 7.94), which meant the relative data were not enough to draw a conclusion ( Figure 4.1 and 4.2 ) .
Diastolic pressure
The heterogeneity on diastolic pressure changes ( I ² = 16%, p = 0.31, Chi² = 3.55) was acceptable. We used a fixedeffects model to analyze the data. From the four studies, we could draw the conclusion that L-arginine was more effective at reducing the diastolic pressure than placebo (MD 4.86; 95% CL 4.19, 5.52) ( Figure 5 ).
Neonatal weight
Six hundred and fifteen participants from four studies were enrolled in the neonatal weight analysis, the heterogeneity of which ( I ² = 39%, p = 0.18, Chi² = 4.94) was acceptable, so the fixed-effects model was used. There was no statistically significant difference between L-arginine and placebo group (MD − 50.27; 95% CL − 136.27, 35.72), which meant the relative data were not enough to draw the conclusion that L-arginine can make neonates gain weight rather than placebo ( Figure 6 ).
Adverse effect
Only three studies reported adverse effects ( Table 5 ) . No teratogenic or lethal effects were reported. The risk of arginine administration seemed uncommon.
Sensitivity analysis
In order to assess reporting bias, a sensitivity analysis was conducted, including the Neri et al. study, 23 which was first excluded from the meta-analysis mentioned above. The result showed that the difference of systolic pressure became significant, while that of diastolic pressure remained the same, which meant caution should be used to draw conclusions from the meta-analysis.
Discussion
Circulating L-arginine is the matrix of NO synthase, while NO, an endothelial-derived vasodilator, has been confirmed as a synthesis defect in patients with preeclampsia. 9 , 28 NO is a free radical, playing a fundamental role in physiology, maintaining the stabilization of homeostasis, cardiovascular activity, and immune responses. NO plays a very important role in obstetrics procedures, such as delivery, cervical ripening, occurrence of preeclampsia, and intrauterine growth retardation. During human and animal pregnancy, the blood vessels make a series of adaptive changes because of blood volume gain, cardiac output increase, and reduced vascular tolerance, leading to increase of NO production. The absence of L-arginine, an important NO donor, results in gestational hypertension. Facchinetti et al.'s study had demonstrated that the L-arginine supplement could significantly decrease blood pressure in preeclampsia patients. 29 It is well known that hypertensive disorder in pregnancy is Figure 6 . Forest plot of the diastolic pressure between L-arginine and placebo: fixed-effects model. Table 5 . Adverse effects of arginine supplementation.
Studies Adverse reaction
Vadillo-Ortega et al. 31 Nausea, dyspepsia, dizziness, palpitations, and headache Facchinetti et al. 29 Diarrhea in three patients during oral L-Arg treatment Hladunewich et al. 36 One percent to − 10% of subjects had headache, nausea, vomiting, and numbness Neri et al. 23 No adverse effect reported Rytlewski et al. 33 No adverse effect reported Staff et al. 34 No adverse effect reported L-Arg: L-arginine.
an important cause of maternal and neonatal mortality, contributing to 10%−15% of maternal mortality in developing countries, and even 18% of deaths in pregnant women due to hypertensive disease in the United States. 30 Therefore, it is important to demonstrate whether L-arginine is beneficial for pregnant women with hypertension disorder. In this meta-analysis the data, extracted from existing randomized controlled studies of L-arginine, including eclampsia incidence, incubation period, blood pressure in pregnancy, and neonatal birth weight, revealed the apparent lower incidence of preeclampsia or eclampsia in the L-arginine supplement group, but the number of studies was fairly small. What's more, the study by Vadillo-Ortega et al. 31 enrolled only pregnant women with high risks, which made the baseline unbalanced. As a result, whether the conclusion should be restricted to specific participants with a history of a previous pregnancy complicated by preeclampsia, or preeclampsia in a first-degree relative and deemed to be at increased risk of recurrence, was questionable. Although the methods and dosage were not the same, the result provided a good idea for our primary prevention in high-risk pregnant women. Our study also suggested that L-arginine could prolong latency (duration of pregnancy), which may help the prevention of preterm birth.
Interestingly, L-arginine supplementation can distinctly decrease diastolic blood pressure, while the impact on systolic blood pressure was not clear. The previous studies also showed that systolic and diastolic blood pressure were apparently reduced after supplementation of L-arginine; however, the decline of systolic blood pressure was not statistically significant. 32 We cannot find a reasonable explanation for the major effect on diastolic blood pressure, which requires further studies.
Among all the studies, the intervention methods were complex, including administration routes and dosages. There were two routes, such as oral and intravenous, and the former one seemed to be much related to gastrointestinal adverse effects (Table 5 ). And the dosage range was from 3 g to 30 g, which made the baseline of these studies inhomogeneous ( Table 1) .
The Jadad scores of enrolled trials were all higher than 4, which meant the qualities of these trials were in an acceptable range. The results showed that L-arginine can reduce diastolic pressure and prolong pregnancy better than placebo, but the effects on systolic pressure and neonatal weight were not clear.
There were several limitations in our meta-analysis. First, we included eight RCTs, two of which were from the same research project; one trial was excluded because of uncertain quality, and one trial showed data only in figures. For these reasons, the number of enrolled trials was very small. Second, the sample sizes of these trials were quite small. The participants involved in the preeclampsia incidence analysis were only 267 in the L-arginine group and 257 in the placebo group, while the participants involved in the blood pressure analysis were only 103 in the L-arginine group and 101 in the placebo group. Third, the Jadad score of Rytlewski et al.'s 33 study was 4 but the number of enrolled subjects was large, which will bring uncertainty biases to the final result of the meta-analysis. Fourth, the outcome evaluations were different from each study. It was very difficult for the reviewers to get necessary information. The gestational age and the severity of hypertensive disorders were not available. In summary, conclusions may be drawn with caution.
